These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32987920)

  • 21. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
    Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
    Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
    Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
    Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined analytical approaches to define biodistribution and biological activity of semi-synthetic berberrubine, the active metabolite of natural berberine.
    Porru E; Franco P; Calabria D; Spinozzi S; Roberti M; Caliceti C; Roda A
    Anal Bioanal Chem; 2018 Jun; 410(15):3533-3545. PubMed ID: 29411090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition: Oxidation Behavior and Metabolite-Mediated Inhibition.
    Lo SN; Shen CC; Chang CY; Tsai KC; Huang CC; Wu TS; Ueng YF
    Drug Metab Dispos; 2015 Jul; 43(7):1100-7. PubMed ID: 25953522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6.
    Fischer V; Vogels B; Maurer G; Tynes RE
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1355-60. PubMed ID: 1545398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.
    Reinen J; Smit M; Wenker M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):737-750. PubMed ID: 29785610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6.
    Umeda S; Harakawa N; Yamamoto M; Ueno K
    Biol Pharm Bull; 2005 Feb; 28(2):212-6. PubMed ID: 15684471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.
    Haritos VS; Ching MS; Ghabrial H; Gross AS; Taavitsainen P; Pelkonen O; Battaglia SE; Smallwood RA; Ahokas JT
    Pharmacogenetics; 1998 Oct; 8(5):423-32. PubMed ID: 9825834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
    Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
    Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes.
    Liu L; Sun S; Rui H; Li X
    Pharm Biol; 2017 Dec; 55(1):1868-1874. PubMed ID: 28614988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and characterization of potent CYP2D6 inhibitors in lotus leaves.
    Ye LH; He XX; Kong LT; Liao YH; Pan RL; Xiao BX; Liu XM; Chang Q
    J Ethnopharmacol; 2014 Apr; 153(1):190-6. PubMed ID: 24561383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
    Prakash C; Kamel A; Cui D; Whalen RD; Miceli JJ; Tweedie D
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):35S-42S. PubMed ID: 10771452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.
    Springer D; Staack RF; Paul LD; Kraemer T; Maurer HH
    Xenobiotica; 2003 Oct; 33(10):989-98. PubMed ID: 14555336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism-based inactivation of cytochrome P450 2D6 by Notopterol.
    Fu Y; Tian X; Han L; Li Y; Peng Y; Zheng J
    Chem Biol Interact; 2020 May; 322():109053. PubMed ID: 32198085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
    Kudo S; Odomi M
    Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.